•
Sep 26, 2020

Hologic Q4 2020 Earnings Report

Hologic's Q4 2020 financial performance was driven by strong sales of COVID tests, resulting in a 55.6% increase in revenue and GAAP diluted EPS of $1.88.

Key Takeaways

Hologic, Inc. reported strong financial results for the fourth quarter of fiscal year 2020, with revenue increasing by 55.6% to $1.347 billion. The company's performance was driven by strong sales of COVID-19 tests, which offset declines in other businesses. GAAP diluted EPS was $1.88, and non-GAAP diluted EPS was $2.07.

Revenue increased 55.6% for the quarter, or 54.2% in constant currency.

Organic revenue in the fourth quarter increased 72.5%, or 70.9% in constant currency.

GAAP earnings per share (EPS) were $1.88, compared to ($0.46) in the prior year period.

Non-GAAP EPS of $2.07 increased 218.5% over the prior year period.

Total Revenue
$1.35B
Previous year: $866M
+55.6%
EPS
$2.07
Previous year: $0.65
+218.5%
Gross Profit
$932M
Previous year: $387M
+141.0%
Cash and Equivalents
$701M
Previous year: $602M
+16.5%
Free Cash Flow
$397M
Previous year: $229M
+73.7%
Total Assets
$7.2B
Previous year: $6.44B
+11.7%

Hologic

Hologic

Hologic Revenue by Segment

Hologic Revenue by Geographic Location

Forward Guidance

Hologic expects strong financial performance to continue in the first quarter of fiscal 2021, driven by COVID tests and continued recovery of other businesses.

Positive Outlook

  • Revenue between $1.35 billion and $1.425 billion
  • Reported revenue increase of 58.7% to 67.6%
  • Constant currency revenue increase of 56.6% - 65.4%
  • Organic revenue increase of 71.1% - 80.8%
  • Non-gaap EPS between $2.10 and $2.25

Revenue & Expenses

Visualization of income flow from segment revenue to net income